Sulzer Medica begins trials of new implantable cardioverter-defibrillator (ICD):
This article was originally published in Clinica
Executive Summary
A Canadian woman has become the first patient to receive a new implantable cardioverter-defibrillator capable of distinguishing life threatening irregular heart beats from their non fatal counterparts. The Res-Q Micron Advantage, developed by Sulzer Medica, is designed to deliver electric shocks to treat ventricular arrhythmias while preventing unnecessary shocks to patients with non-ventricular arrhythmias.